Cargando…

Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores

Bleeding risk represents a major concern in anticoagulated patients with atrial fibrillation (AF). Several bleeding prediction scores have been described: HAS-BLED, ATRIA, HEMORR(2)HAGES and ORBIT. Of these, only HAS-BLED considers quality of anticoagulation control amongst vitamin K antagonist (VKA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Proietti, Marco, Senoo, Keitaro, Lane, Deirdre A., Lip, Gregory Y. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828703/ https://www.ncbi.nlm.nih.gov/pubmed/27067661 http://dx.doi.org/10.1038/srep24376

Ejemplares similares

Stroke and Bleeding Risk in Atrial Fibrillation
por: Senoo, Keitaro, et al.
Publicado: (2014)

Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials
por: Proietti, Marco, et al.
Publicado: (2016)

Stroke and bleeding risk stratification in atrial fibrillation: a critical appraisal
por: Lane, Deirdre A, et al.
Publicado: (2020)

Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients
por: Deitelzweig, Steven, et al.
Publicado: (2021)

Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation
por: Rivera-Caravaca, José Miguel, et al.
Publicado: (2017)

Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies
por: Ding, Wern Yew, et al.
Publicado: (2020)

Major Bleeding Complications and Persistence With Oral Anticoagulation in Non‐Valvular Atrial Fibrillation: Contemporary Findings in Real‐Life Danish Patients
por: Lamberts, Morten, et al.
Publicado: (2017)

Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS‐BLED and GARFIELD‐AF Bleeding Scores
por: Proietti, Marco, et al.
Publicado: (2018)

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
por: Tepper, Ping G., et al.
Publicado: (2018)

Anticoagulation Control and Major Adverse Clinical Events in Patients with Operated Valvular Heart Disease with and without Atrial Fibrillation Receiving Vitamin K Antagonists
por: Zulkifly, Hanis H., et al.
Publicado: (2023)

Major Bleeding Risk in Patients With Non-valvular Atrial Fibrillation Concurrently Taking Direct Oral Anticoagulants and Antidepressants
por: Chang, Kuo-Hsuan, et al.
Publicado: (2022)

Thromboembolism and Major Bleeding in Patients with Atrial Fibrillation and EHRA Type 2 Valvular Heart Disease: The Jordan Atrial Fibrillation (JoFib) Study
por: Al-Najar, Mahasen, et al.
Publicado: (2023)

Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States
por: Lip, Gregory Y. H., et al.
Publicado: (2016)

The CHA(2)DS(2)-VASc Score Predicts Major Bleeding in Non-Valvular Atrial Fibrillation Patients Who Take Oral Anticoagulants
por: Lee, Kuang-Tso, et al.
Publicado: (2018)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation
por: O'Brien, Emily C., et al.
Publicado: (2015)

Do Apixaban Plasma Levels Relate to Bleeding? The Clinical Outcomes and Predictive Factors for Bleeding in Patients with Non-Valvular Atrial Fibrillation
por: Limcharoen, Sutee, et al.
Publicado: (2022)

Bleeding Risk Scores in Atrial Fibrillation: Helpful or Harmful?
por: Edmiston, Marissa K., et al.
Publicado: (2018)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases
por: Lip, Gregory Y. H., et al.
Publicado: (2022)

Risk of major bleeding at different PT-INR ranges in elderly Japanese patients with non-valvular atrial fibrillation receiving warfarin: a nested case-control study
por: Ohgushi, Atsushi, et al.
Publicado: (2016)

Aortic valve stenosis provides complementary information to bleeding risk scores in non-valvular atrial fibrillation patients initiating anticoagulation
por: Elvira-Ruiz, Ginés, et al.
Publicado: (2020)

Contemporary management of atrial fibrillation in primary and secondary care in the UK: the prospective long-term AF-GEN-UK Registry
por: Shantsila, Alena, et al.
Publicado: (2022)

Associations of anemia with death and major bleeding in patients with atrial fibrillation: A report from the Chinese Atrial Fibrillation Registry Study
por: Zhang, Zhuxin, et al.
Publicado: (2021)

Low Body Weight Increases the Risk of Ischemic Stroke and Major Bleeding in Atrial Fibrillation: The COOL-AF Registry
por: Krittayaphong, Rungroj, et al.
Publicado: (2020)

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
por: Kirchhof, Paulus, et al.
Publicado: (2020)

Clinical Features and Prognosis in Patients with Atrial Fibrillation and Prior Stroke: Comparing the Fushimi and Darlington AF Registries
por: Ogawa, Hisashi, et al.
Publicado: (2017)

Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis
por: Sakuma, Ichiro, et al.
Publicado: (2019)

Racial differences in atrial fibrillation-related bleeding and mortality
por: Kang, D S, et al.
Publicado: (2023)

In-hospital direct costs for thromboembolism and bleeding in Chinese patients with atrial fibrillation
por: Chang, San-Shuai, et al.
Publicado: (2018)

Comprehensive Management With the ABC (Atrial Fibrillation Better Care) Pathway in Clinically Complex Patients With Atrial Fibrillation: A Post Hoc Ancillary Analysis From the AFFIRM Trial
por: Proietti, Marco, et al.
Publicado: (2020)

Correction to: Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis
por: Sakuma, Ichiro, et al.
Publicado: (2019)

Real‐world data on the incidence, mortality, and cost of ischaemic stroke and major bleeding events among non‐valvular atrial fibrillation patients in England
por: Bakhai, Ameet, et al.
Publicado: (2020)

Assessing bleeding risk in 4824 Asian patients with atrial fibrillation: The Beijing PLA Hospital Atrial Fibrillation Project
por: Guo, Yu-tao, et al.
Publicado: (2016)

Causes of death of patients with non-valvular atrial fibrillation in Asians
por: Krittayaphong, Rungroj, et al.
Publicado: (2023)

Non-Vitamin K Oral Anticoagulants Assessment in High Risk of Bleeding Patients with Non-Valvular Atrial Fibrillation
por: Silva Cunha, Pedro, et al.
Publicado: (2022)

Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis
por: Wang, Cen, et al.
Publicado: (2017)

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
por: Bahit, M Cecilia, et al.
Publicado: (2017)

Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2020)

Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants
por: Ording, Anne Gulbech, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bnngktbenq8drst7jeu8thgosh